Currently out of the existing stock ratings of Nicole Germino, 12 are a BUY (80%), 3 are a HOLD (20%).

Nicole Germino

Work Performance Price Targets & Ratings Chart

Analyst Nicole Germino, currently employed at TRUIST, carries an average stock price target met ratio of 13.33% that have a potential upside of 12.99% achieved within 40 days.

Nicole Germino’s has documented 24 price targets and ratings displayed on 5 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on SGMO, Sangamo Therapeutics at 13-Dec-2024.

Wall Street Analyst Nicole Germino

Analyst best performing recommendations are on PNT (POINT BIOPHARMA GLOBAL).
The best stock recommendation documented was for PNT (POINT BIOPHARMA GLOBAL) at 11/15/2022. The price target of $14 was fulfilled within 388 days with a profit of $7.89 (129.13%) receiving and performance score of 3.33.

Average potential price target upside

ASMB Assembly Biosciences FBRX Forte Biosciences SGMO Sangamo Therapeutics PNT POINT Biopharma Global FUSN Fusion Pharmaceuticals 

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

25 days ago
(27-Dec-2024)

3/4 (75%)

$5.52 (44.23%)

188

Hold

$35

$20.51 (141.55%)

$84

4 months 1 days ago
(20-Sep-2024)

2/8 (25%)

$15.57 (80.13%)

51

Buy

$24

$9.51 (65.63%)

2 years 2 months 28 days ago
(24-Oct-2022)

0/2 (0%)

$4.8 (25.00%)

Buy

$12

$-1.72 (-12.54%)

$15

2 years 9 months 20 days ago
(01-Apr-2022)

2/2 (100%)

$-12.72 (-51.46%)

502

Buy

$168

$153.51 (1059.42%)

$168

3 years 4 months 18 days ago
(03-Sep-2021)

1/5 (20%)

$128.88 (329.45%)

57

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Nicole Germino is most bullish on?

Potential upside of $5.91 has been obtained for SGMO (SANGAMO THERAPEUTICS)

What Year was the first public recommendation made by Nicole Germino?

On 2020

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?